Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

NCT00303810 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 567

Last updated 2014-01-28

No results posted yet for this study

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy in different ways and giving it together with more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which radiation therapy and combination chemotherapy regimen is more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), or ependymoma.

PURPOSE: This clinical trial is studying six different radiation therapy and combination chemotherapy regimens to compare how well they work in treating young patients with medulloblastoma, PNET, or ependymoma.

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: carboplatin
DRUG: cisplatin
DRUG: cyclophosphamide
DRUG: etoposide phosphate
DRUG: high-dose chemotherapy
DRUG: lomustine
DRUG: methotrexate
DRUG: thiotepa
DRUG: vincristine sulfate
RADIATION: radiation therapy

Sponsors & Collaborators

Universitätsklinikum Hamburg-Eppendorf
lead OTHER

Principal Investigators

Stefan Rutkowski, MD · University Med. Center Hamburg, Dpt. of Pediatric Hematology and Oncology
Frank Deinlein, MD · Universitaets - Kinderklinik Wuerzburg

Study Design

Purpose: TREATMENT
Masking: NONE

Eligibility

Max Age: 21 Years
Sex: ALL
Healthy Volunteers: No

Timeline & Regulatory

Start: 2001-01-31
Primary Completion: 2013-12-31

Countries

Germany

Study Locations

More Related Trials

Entities

Drugs

Diseases

Brain and Central Nervous System Tumors